van der Ploeg Eline A, Hylkema Tjerk H, Gan C Tji
Department of Respiratory Diseases, Tuberculosis and Lung Transplantation, University of Groningen, University Medical Center, Groningen, The Netherlands.
Curr Opin Pulm Med. 2025 Jul 1;31(4):354-358. doi: 10.1097/MCP.0000000000001176. Epub 2025 Apr 25.
Over the past decade, increased knowledge has contributed to improved medical and technical treatments across the spectrum of respiratory diseases. As a result, timing for transplant evaluation might be more challenging. In this review, the focus is on timing of lung transplant evaluation of patients from the main respiratory diseases referred. Disease-specific predictors of survival in relation to timing of transplant evaluation and alternative treatments will be reviewed.
Treatment options have evolved for respiratory diseases like chronic obstructive pulmonary disease, pulmonary fibrosis, cystic fibrosis and pulmonary arterial hypertension. These treatments have led to improved quality of life, exercise tolerance, lung function and outcome. However, the effect of these alternative treatments on transplant candidacy and knowledge on timing of lung transplant evaluation are lacking.
This article reviews the current best evidence to guide clinicians regarding the optimum timing for transplant referral and highlights considerations to optimize transplant candidacy and outcomes.
在过去十年中，知识的增长推动了各类呼吸系统疾病医疗和技术治疗水平的提高。因此，移植评估的时机选择可能更具挑战性。在本综述中，重点关注转诊的主要呼吸系统疾病患者的肺移植评估时机。将对与移植评估时机和替代治疗相关的特定疾病生存预测因素进行综述。
慢性阻塞性肺疾病、肺纤维化、囊性纤维化和肺动脉高压等呼吸系统疾病的治疗选择不断发展。这些治疗改善了生活质量、运动耐量、肺功能和治疗结果。然而，这些替代治疗对移植候选资格的影响以及肺移植评估时机的相关知识尚显不足。
本文综述了当前最佳证据，以指导临床医生确定移植转诊的最佳时机，并强调优化移植候选资格和治疗结果的注意事项。
